NCT04023916 is a Phase 2 clinical trial of Sintilimab-R-CHOP in Diffuse Large B-Cell Lymphoma, sponsored by Chinese Academy of Medical Sciences.

Who is sponsoring NCT04023916?

NCT04023916 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT04023916?

Interventions in NCT04023916: Sintilimab-R-CHOP.

What condition does NCT04023916 study?

NCT04023916 studies Diffuse Large B-Cell Lymphoma, Sintilimab, TP53 Mutation.

Is NCT04023916 still recruiting?

NCT04023916 is currently status unknown. Last updated 11 December 2019.

Last reviewed 2019-12-11 · How we verify

NCT04023916

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

Status unknown Phase 2 Last updated 11 December 2019

What this trial tests

Phase 2 trial testing Sintilimab-R-CHOP in Diffuse Large B-Cell Lymphoma in 30 participants. Status unknown.

Timeline

1 December 2019

Primary endpoint
30 July 2020

30 July 2021

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 December 2019
Primary completion	30 July 2020
Estimated completion	30 July 2021

Drugs / interventions tested

Sintilimab-R-CHOP — full drug profile →

Conditions studied

Diffuse Large B-Cell Lymphoma — all drugs for Diffuse Large B-Cell Lymphoma →
Sintilimab — all drugs for Sintilimab →
TP53 Mutation — all drugs for TP53 Mutation →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

Adults 18 to 70, any sex, with Diffuse Large B-Cell Lymphoma or Sintilimab. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics.
Škubník J, Pavlíčková VS, Ruml T, Rimpelová S. · · 2021 · cited 86× · PMID 34571726 · DOI 10.3390/biology10090849
Current insights and future directions of Li-Fraumeni syndrome.
Hosseini MS. · · 2024 · cited 7× · PMID 39404911 · DOI 10.1007/s12672-024-01435-w
The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS.
Li JW, Deng C, Zhou XY, Deng R. · · 2024 · cited 7× · PMID 38234917 · DOI 10.1016/j.heliyon.2023.e23921

Verify or expand the search:

Other recruiting trials for Diffuse Large B-Cell Lymphoma

Currently open trials in the same condition.

NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07200375 — An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma · recruiting
NCT07070648 — Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ct · recruiting
NCT07001540 — Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola · Phase 2 · recruiting
NCT06803693 — Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL · Phase 2 · recruiting

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04023916 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 11 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04023916.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing